U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H5O3.C5H14NO
Molecular Weight 241.2836
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHOLINE SALICYLATE

SMILES

C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O

InChI

InChIKey=UDKCHVLMFQVBAA-UHFFFAOYSA-M
InChI=1S/C7H6O3.C5H14NO/c8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7/h1-4,8H,(H,9,10);7H,4-5H2,1-3H3/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C7H6O3
Molecular Weight 138.1207
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C5H13NO
Molecular Weight 103.1628
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html

Methyl salicylate (or methyl 2-hydroxybenzoate), also known as wintergreen oil, is a natural product and is present in white wine, tea, porcini mushroom Boletus edulis, Bourbon vanilla, clary sage, red sage and fruits including cherry, apple, raspberry, papaya and plum. Methyl salicylate is topically used in combination with methanol and under brand name SALONPAS to temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises. The precise mechanism of action of methyl salicylate is not known, but there is suggested, that it cause dilation of the capillaries thereby increasing blood flow to the area.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.48 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

2012
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

2012
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

2012
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
238 min
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SALICYLIC ACID plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Other AEs: Redness, Scales...
Other AEs:
Redness
Scales
Sources:
AEs

AEs

AESignificanceDosePopulation
Redness
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Scales
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
major
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
Effects of salicylates on evoked otoacoustic emissions and remote masking in humans.
1999 May-Jun
Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis.
1999 Sep
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
2001
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries.
2001
The solvent shells of cluster ions produced by direct electric field extraction from glycerol/water mixtures.
2001
Arabidopsis genome sequence as a tool for functional genomics in tomato.
2001
Unraveling regulatory networks in plant defense using microarrays.
2001
Abnormal callose response phenotype and hypersusceptibility to Peronospoara parasitica in defence-compromised arabidopsis nim1-1 and salicylate hydroxylase-expressing plants.
2001 Apr
Nitric oxide: comparative synthesis and signaling in animal and plant cells.
2001 Apr
Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT.
2001 Apr
Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on nitric oxide-induced hydroxyl radical generation in the rat heart.
2001 Apr 30
Non-ionic micellar affinity capillary electrophoresis for analysis of interactions between micelles and drugs.
2001 Feb
Estrogenic activity of phenolic additives determined by an in vitro yeast bioassay.
2001 Feb
A hot pepper cDNA encoding a pathogenesis-related protein 4 is induced during the resistance response to tobacco mosaic virus.
2001 Feb 28
Non-uniform mapping of stress-induced, motility-related charge movement in the outer hair cell plasma membrane.
2001 Jan
Increases in the mutation frequency at which fusidic acid-resistant Staphylococcus aureus arise with salicylate.
2001 Jan
Guidelines for the management of cutaneous warts.
2001 Jan
Ion channel-forming alamethicin is a potent elicitor of volatile biosynthesis and tendril coiling. Cross talk between jasmonate and salicylate signaling in lima bean.
2001 Jan
The possibility of achieving an interactive mixture with high dose homogeneity containing an extremely low proportion of a micronised drug.
2001 Jan
Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism.
2001 Jan 15
Quantitative analysis of crystalline pharmaceuticals in powders and tablets by a pattern-fitting procedure using X-ray powder diffraction data.
2001 Jan 16
Synthesis and metal binding properties of salicylate-, catecholate-, and hydroxypyridinonate-functionalized dendrimers.
2001 Jan 5
Release of salicylic acid, diclofenac acid and diclofenac acid salts from isotropic and anisotropic nonionic surfactant systems across rat skin.
2001 Jan 5
Increased sensitivity to sodium salicylate-induced apoptosis in drug-resistant leukemia L1210 cells.
2001 Jan-Feb
A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus.
2001 Jul 6
Development of QSARs to investigate the bacterial toxicity and biotransformation potential of aromatic heterocylic compounds.
2001 Mar
Effect of lipophilicity on in vivo iontophoretic delivery. I. NSAIDs.
2001 Mar
Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals.
2001 May
Acanthoamoeba attachment to contact lenses.
2001 May
Binding of cosalane--a novel highly lipophilic anti-HIV agent--to albumin and glycoprotein.
2001 May
6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum.
2001 May 8
Patents

Sample Use Guides

The preferable method of use is to apply Salicylic Acid 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for a least five minutes prior to application.
Route of Administration: Topical
In Vitro Use Guide
Salicylic acid inhibited hippuric acid formation in the homogenates obtained from the specimens of human liver with IC50 value 0.19 mM
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:02:46 GMT 2023
Edited
by admin
on Fri Dec 15 15:02:46 GMT 2023
Record UNII
KD510K1IQW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHOLINE SALICYLATE
INN   JAN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
CHOLINE SALICYLATE [VANDF]
Common Name English
BENZOIC ACID, 2-HYDROXY-, ION(1-), 2-HYDROXY-N,N,N-TRIMETHYLETHANAMINIUM
Common Name English
(2-HYDROXYETHYL)TRIMETHYL AMMONIUM SALICYLATE
Systematic Name English
CHOLINE SALICYLATE [MI]
Common Name English
CHOLINE SUBSALICYLATE
Common Name English
SALICYLIC ACID, ION(1-), CHOLINE
Common Name English
CHOLINE SALICYLATE [USAN]
Common Name English
CHOLINE SALICYLATE [MART.]
Common Name English
SALICYLIC ACID CHOLINE SALT
Common Name English
(2-HYDROXYETHYL)TRIMETHYLAMMONIUM 2-HYDROXYBENZOATE
Systematic Name English
Choline salicylate [WHO-DD]
Common Name English
CHOLINE SALICYLIC ACID SALT
Common Name English
CHOLINE, SALICYLATE (SALT)
Common Name English
ETHANAMINIUM, 2-HYDROXY-N,N,N-TRIMETHYL-, 2-HYDROXYBENZOATE (1:1)
Systematic Name English
CHOLINE SALICYLATE [JAN]
Common Name English
choline salicylate [INN]
Common Name English
ETHANAMINIUM, 2-HYDROXY-N,N,N-TRIMETHYL-, SALT WITH 2-HYDROXYBENZOIC ACID (1:1)
Common Name English
Classification Tree Code System Code
WHO-ATC N02BA03
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
WHO-VATC QN02BA03
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
NCI_THESAURUS C257
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
Code System Code Type Description
SMS_ID
100000092173
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
PRIMARY
EVMPD
SUB06219MIG
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
PRIMARY
DRUG BANK
DB14006
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
PRIMARY
CAS
2016-36-6
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
PRIMARY
ECHA (EC/EINECS)
217-948-8
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
PRIMARY
EPA CompTox
DTXSID8062103
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
PRIMARY
NCI_THESAURUS
C76798
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
PRIMARY
MERCK INDEX
m3483
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL2104095
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
PRIMARY
PUBCHEM
54686350
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
PRIMARY
DAILYMED
KD510K1IQW
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
PRIMARY
RXCUI
20974
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
PRIMARY RxNorm
INN
1938
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
PRIMARY
MESH
C015075
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
PRIMARY
FDA UNII
KD510K1IQW
Created by admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY